- Reuters•2 hours ago
The U.S. Food and Drug Administration (FDA) on Tuesday approved Roche Holding AG's multiple sclerosis (MS) drug Ocrevus, putting the potential blockbuster drug back on track after a delay caused by regulators' concerns over manufacturing issues. The infusible drug, known chemically as ocrelizumab, becomes the first U.S.-approved medicine for the primary progressive form of the neurological disease (PPMS). It is also approved to treat the most common form of the disease, known as relapsing-remitting multiple sclerosis (RRMS).
- Insider Monkey•2 days ago
The 10 biggest recent accounting scandals in America have shaken the nation and affected investor confidence. Though not all scandals are the same, they tend to lead to large investor losses and depending on the magnitude of the scandal, may even affect confidence in the financial system at large. Corporate accounting scandals are by no […]
- Zacks•2 days ago
Merck & Co., Inc. (MRK) recently announced that its anti-PD-1 therapy, Keytruda, has received positive opinion from CHMP for the treatment of patients with relapsed or refractory classical hodgkin lymphoma (cHL).
MRK : Summary for Merck & Company, Inc. Common St - Yahoo Finance
Merck & Co., Inc. (MRK)
NYSE - NYSE Delayed Price. Currency in USD
Add to watchlist
|Day's Range||62.88 - 63.40|
|52 Week Range||52.44 - 66.80|
Trade prices are not sourced from all markets
|PE Ratio (TTM)||44.92|
|Dividend & Yield||1.88 (2.98%)|
|1y Target Est||N/A|